Conference Proceedings

A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)

KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, G Lo, B Tran, A Azad, L Wood, JR Gingerich, S North, CV Pezaro, D Ruether, SS Sridhar, M Annala, J Bacon, AW Wyatt

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2018

Grants

Funding Acknowledgements

Sanofi Genzyme, Prostate Cancer Canada Movember Disxcovery Grant, Canadian Institutes of Health Research Project Grant, Terry Fox Research Institute Program Project Grant.